Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Franklin Biotechnology Discovery Fund Class A (FBDIX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.


1 month+1.28% 3 years+11.57%
3 months+9.11% 5 years+19.47%
1 year+16.78% Since inception+11.75%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return+19.47%+16.30%
Expense ratio1.00%1.33%
Risk 5 year sharpe ratio0.861.05
Net assets$1.4B$3.0B
Average market cap$8.7B$29.5B
Average P/E--24.1
Portfolio turnover22%22%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFranklin Templeton Investments
Fund manager & tenureEvan McCulloch / 19 Years
Minimal initial investment$1,000.00
Minimum IRA investment$250.00


U.S. stock93.26%
International stock3.04%
Fixed income1.22%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
CELG Celgene9.61%
BIIB Biogen6.56%
INCY Incyte Corp6.40%
ALXN Alexion Pharmaceuticals Inc5.57%
REGN Regeneron Pharmaceuticals4.64%
GILD Gilead Sciences4.16%
AMGN Amgen4.14%
VRTX Vertex Pharmaceuticals Inc3.56%
ILMN Illumina Inc2.67%